Korean Circ J.  2020 Jul;50(7):543-554. 10.4070/kcj.2020.0205.

Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives

• Kim IC
• Kim HA
• Park JS
• Nam CW

• KMID: 2504213
• DOI: http://doi.org/10.4070/kcj.2020.0205

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. Not just respiratory complications such as pneumonia and acute respiratory distress syndrome, cardiac manifestations have drawn attention due to the increased risk of mortality and morbidity related to SARS-CoV-2 infections. The mechanisms of the cardiac injury related to SARS-CoV-2 infections have been direct cardiac injury caused by angiotensin converting enzyme 2, hypoxemia, microvascular damage, and a systemic inflammatory response. Stress induced cardiomyopathy in a critically ill condition and acute coronary syndrome due to a vulnerable plaque rupture with coagulopathy can finally lead to acute heart failure with further cardiac manifestations. When dealing with the highly contagious viral disease-related cardiac manifestations, we should carefully apply the diagnostic and therapeutic methods to achieve the best therapeutic results without adding any risk of disease transmission.

Keyword

Coronavirus; COVID-19; SARS-CoV-2; Heart; Cardiac manifestation; Cardiac injury

Figure

• 

  Figure 1 The trend of COVID-19 confirmed patients in South Korea until May 31, 2020. The total numbers in Korea are depicted in the blue line and numbers in Daegu/North Gyeongsang province are depicted in the red line.COVID-19 = coronavirus disease 2019.

• 

  Figure 2 Evaluation for the cardiac manifestation in COVID-19 and diagnostic algorithm of COVID-19 associated cardiac injury.COVID-19 = coronavirus disease 2019; CT = computed tomography; URL = upper reference limit.

• 

  Figure 3 Mechanism of myocarditis and acute cardiac injury by SARS-CoV-2 leading to acute heart failure.SARS-CoV-2 = severe acute respiratory syndrome-coronavirus 2; ACE = angiotensin converting enzyme; CMP = cardiomyopathy.

Reference

1. World Health Organization. Coronavirus disease (COVID-19) outbreak [Internet]. Geneva: World Health Organization;c2020. cited 2020 May 5. Available from: https://covid19.who.int/.

2. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382:929–936. PMID: 32004427.

3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323:1239.

4. Cho DH, Yoo BS, Son JW, Kim IC, Park SM, Choi DJ. COVID-19 — Implications for patients with heart failure: The Korean Society of Heart Failure's clinical recommendations. Int J Heart Fail. 2020; 2:111–114.

5. Thomson B. The COVID-19 pandemic: a global natural experiment. Circulation. 2020; [Epub ahead of print].

6. Kim JY, Choe PG, Oh Y, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020; 35:e61. PMID: 32030925.

7. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323:1061.

8. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; [Epub ahead of print].

9. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020; [Epub ahead of print].

10. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; [Epub ahead of print].

11. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020; 41:1798–1800. PMID: 32186331.

12. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17:259–260. PMID: 32139904.

13. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289:2801–2809. PMID: 12734147.

14. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003; 58:686–689. PMID: 12885985.

15. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016; 49:129–133. PMID: 27352628.

16. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020; 141:1648–1655. PMID: 32200663.

17. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708–1720. PMID: 32109013.

18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–1062. PMID: 32171076.

19. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–506. PMID: 31986264.

20. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8:475–481. PMID: 32105632.

21. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020; 323:1612.

22. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020; [Epub ahead of print].

23. van Doremalen N, Bushmaker T, Munster VJ. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. Euro Surveill. 2013; 18:20590. PMID: 24084338.

24. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020; 41:1859. PMID: 32282027.

25. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016; 36:78–80. PMID: 26922692.

26. Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz. 2000; 25:200–209. PMID: 10904839.

27. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020; [Epub ahead of print].

28. Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res. 2020; 126:1443–1455. PMID: 32252591.

29. Kim IC, Han S. Epicardial adipose tissue: fuel for COVID-19-induced cardiac injury? Eur Heart J. 2020; [Epub ahead of print].

30. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103:1718–1720. PMID: 11282900.

31. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018; 138:e618–51. PMID: 30571511.

32. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19 - A case series. N Engl J Med. 2020; [Epub ahead of print].

33. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care Med. 2020; [Epub ahead of print].

34. Welt FGP, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from the ACC's Interventional Council and SCAI. J Am Coll Cardiol. 2020; 75:2372–2375. PMID: 32199938.

35. Daniels MJ, Cohen MG, Bavry AA, Kumbhani DJ. Reperfusion of STEMI in the COVID-19 era - Business as usual? Circulation. 2020; [Epub ahead of print].

36. Stefanini GG, Azzolini E, Condorelli G. Critical organizational issues for cardiologists in the COVID-19 outbreak: a frontline experience from Milan, Italy. Circulation. 2020; 141:1597–1599. PMID: 32207994.

37. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75:2352–2371. PMID: 32201335.

38. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020; [Epub ahead of print].

39. Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020; 22:911–915. PMID: 32275347.

40. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012; 379:738–747. PMID: 22185868.

41. Cooper LT Jr. Myocarditis. N Engl J Med. 2009; 360:1526–1538. PMID: 19357408.

42. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015; 12:670–680. PMID: 26194549.

43. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res. 2016; 118:496–514. PMID: 26846643.

44. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81:e13–20. PMID: 32283144.

45. Arrigo M, Gayat E, Parenica J, et al. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail. 2017; 19:201–208. PMID: 27790819.

46. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J. 2017; 47:341–353. PMID: 28567084.

47. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020; 382:1653–1659. PMID: 32227760.

48. Beristain-Covarrubias N, Perez-Toledo M, Thomas MR, Henderson IR, Watson SP, Cunningham AF. Understanding infection-induced thrombosis: lessons learned from animal models. Front Immunol. 2019; 10:2569. PMID: 31749809.

49. Obi AT, Tignanelli CJ, Jacobs BN, et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019; 7:317–324. PMID: 30477976.

50. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18:844–847. PMID: 32073213.

51. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020; 7:e362–3. PMID: 32278361.

52. Gao C, Wang Y, Gu X, et al. Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus. Crit Care Med. 2020; 48:451–458. PMID: 32205590.

53. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020; 382:1679–1681. PMID: 32160451.

54. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382:727–733. PMID: 31978945.

55. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111:2605–2610. PMID: 15897343.

56. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012; 123:649–658. PMID: 22715807.

57. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009; 296:F398–405. PMID: 19004932.

58. Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol. 2012; 351:208–219. PMID: 22200414.

59. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43:970–976. PMID: 15007027.

60. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020; 39:496–497. PMID: 32362394.

61. Ren ZL, Hu R, Wang ZW, et al. Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report. J Heart Lung Transplant. 2020; 39:412–417. PMID: 32362392.

62. DeFilippis EM, Farr MA, Givertz MM. Challenges in heart transplantation in the era of COVID-19. Circulation. 2020; [Epub ahead of print].

63. Kim IC, Hwang I, Kim YS, Kim JB. Successful heart transplantation to a fulminant myocarditis patient during COVID-19 outbreak — Lessons learned. Korean Circ J. 2020; 50:634–637. PMID: 32588574.

64. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 323:1824–1836.

65. Morra ME, Van Thanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018; 28:e1977. PMID: 29664167.

66. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3:e343. PMID: 16968120.

67. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — Preliminary report. N Engl J Med. 2020; NEJMoa2007764.

68. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382:2327–2336. PMID: 32275812.

69. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020; 212:416–420. PMID: 32266987.

70. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020; 34:1503–1511. PMID: 32372026.